Drug Profile
Research programme: hepatitis C virus NS5B polymerase inhibitors - Vertex
Alternative Names: SPD 760Latest Information Update: 16 Jan 2019
Price :
$50
*
At a glance
- Originator Shire Pharmaceuticals Group
- Developer Vertex Pharmaceuticals
- Class Small molecules; Thiophenes
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 19 Feb 2010 Discontinued - Preclinical for Hepatitis C in Canada (unspecified route)
- 19 Feb 2010 Discontinued - Preclinical for Hepatitis C in USA (unspecified route)